Home > Rheumatology > ACR 2021 > Spotlight on Rheumatoid Arthritis > Patients with RA-associated interstitial lung disease benefit from antifibrotic agent

Patients with RA-associated interstitial lung disease benefit from antifibrotic agent

Presented By
Prof. Joshua J. Solomon, National Jewish Health, CO, USA
Conference
ACR 2021
Trial
Phase 2, TRAIL1
The TRAIL1 study is the first trial to demonstrate the efficacy and safety of pirfenidone in patients with rheumatoid arthritis (RA) and associated interstitial lung disease (ILD). In participants receiving the antifibrotic, lung function decline was slowed down, particularly in those with a usual interstitial pneumonia pattern at baseline. Some patients with RA develop progressive fibrosing ILD, characterised by increasing fibrosis on high-resolution CT, a decline in lung function, worsening symptoms, and high mortality. Patients with RA have a lifetime risk of 7.7% for this complication, which is an 8-time higher relative risk to develop ILD compared with the general population [1]. Previously, the antifibrotic agent nintedanib has shown benefits in patients with autoimmune-associated ILD [2]. Up to now, no completed treatment trials exclusively for RA subjects with ILD exist. This was the rationale to perform the TRAIL1 (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on